Please login to the form below
advanced breast cancer
This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.
Strong five-year survival data for Kisqali in breast cancer
Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer. ... evaluating Kisqali compared to palbociclib in patients with HR+/HER2- advanced breast cancer with aggressive
Latest news
-
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer. ... Pfizer and US biopharma company Arvinas have signed a collaboration agreement to jointly develop and
-
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
Novartis has revealed new data from a phase 3 trial evaluating its targeted radioligand therapy (RLT) in late stage advanced prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) ... advanced breast cancer.
-
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
A US Food and Drug Administration (FDA) panel has voted in favour of maintaining the accelerated approval for Roche’s Tecentriq in breast cancer, amid a major review of cancer drugs ... We are grateful to the FDA and ODAC for the open dialogue and look
-
Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
The phase 1/2 LIBRETTO-001 trial – presented at the virtual American Association for Cancer Research (AACR) annual meeting – enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, ... including pancreatic, colon, breast and
-
Sanofi pays $160m upfront to acquire Tidal Therapeutics
with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types. ... BioNTech also has a number of mRNA-based candidates in development for the treatment of a number of cancer types, including advanced melanoma,
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
Sanofi pays $160m upfront to acquire Tidal Therapeutics
More from news
Approximately 1 fully matching, plus 164 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
advanced or refractory HER2-positive metastatic breast cancer, DS-8201 was recently approved by the FDA with the brand name Enhertu for the treatment of adult patients with unresectable or metastatic ... HER2 positive breast cancer who have received two
-
Leading AstraZeneca’s return to growth in Europe
The drug has so far gained approval for use in patients with germline BRCA1/2-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer, ... That’s a measure of its heightened ambitions in
-
The handover: Pfizer reshapes itself for a new era
Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
-
Digital disruption
Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.
20 for 2020 – Five pharma companies to watch
Leading AstraZeneca’s return to growth in Europe
The handover: Pfizer reshapes itself for a new era
Digital disruption
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
Battling breast cancer with precision medicine (Part 1)
She told me I had advanced breast cancer and urged me to drive down to the local emergency room immediately to get additional tests and start chemotherapy that weekend. ... I was diagnosed with inflammatory breast cancer (IBC) with axillary lymph node
-
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the question if there is an optimal first-line endocrine therapy
-
Indigenus agencies honoured at 2012 Globals, CLIOs and Rx Club Awards
The Fight Forward campaign, an interactive website for patients with advanced breast cancer, took home Silver in the Best Consumer Website and Integrated Campaign categories for the agency.
-
Indigenus Agencies Claim Honors at 2012 Globals, CLIOs, Rx Club Awards
The “Fight Forward” campaign, an interactive website for patients with advanced breast cancer, took home Silver in the Best Consumer Website and Integrated Campaign categories.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Rocky start for Biogen’s Alzheimer’s drug Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- US demand for COVID-19 antibody treatments rising fast
- Our mission: helping patients in areas of unmet medical need
- Novo Nordisk settles US insulin pricing dispute for $100m
- Mysterious big pharma company eyes US biotech Acceleron
- COVID-19 changed change and communications will never be the same
- Understanding behaviour change: A Porterhouse Insights specialism
- Lynparza significantly delays disease progression as first-line treatment in prostate cancer
- David Hunt launches independent agency The Considered
- Live Webinar: Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Lucid Group celebrates a double win at Communiqué 2021
- China backs use of Roche’s Actemra for coronavirus
- Future of MHRA uncertain amid Brexit-fuelled shake up
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Understanding behaviour change: A Porterhouse Insights specialism
- ...
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
